Print

Lay Description

Semaglutide is a medication  approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, Semaglutide has on people who take the drug and the drug’s effect on physical function, body composition, and aging.

Category

  • Aging and Geriatric
  • Diabetes
IRB Number
20220256HU
NCT Number
NCT05786521
Open to Enrollment
Not set

Eligibility

Eligible Ages
Older than 65
Eligible Genders
Male and Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Have prediabetes or diabetes
  • Living independently (not in assisted living or nursing home)

Exclusion Criteria

  • Have heart disease   
  • Have liver disease
  • Smoke

Study Design

Arm Groups

Study Contact

Sandra Idar
(210) 450-0568
idars@uthscsa.edu

Principal Investigator
Tiffany Cortes